These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18614972)

  • 1. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
    Actis GC; Pellicano R; Bugianesi E; Lagget M; Rizzetto M
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):239-42. PubMed ID: 18614972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
    Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.
    Cucchiara S; Romeo E; Viola F; Cottone M; Fontana M; Lombardi G; Rutigliano V; de'Angelis GL; Federici T
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S260-4. PubMed ID: 18598998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
    Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource use in patients with Crohn's disease treated with infliximab.
    Saro C; da la Coba C; Casado MA; Morales JM; Otero B
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1313-23. PubMed ID: 17850419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK; Murray KF
    J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are patients with inflammatory bowel disease receiving optimal care?
    Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
    Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
    Bhatia JK; Korelitz BI; Panagopoulos G; Lobel E; Mirsky F; Sultan K; DiSanti W; Chun A; Keenan G; Mamun K
    J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience.
    Bajaj JS; Saeian K; Varma RR; Franco J; Knox JF; Podoll J; Emmons J; Levy M; Binion DG
    Am J Gastroenterol; 2005 May; 100(5):1121-5. PubMed ID: 15842588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.
    Bolge SC; Waters H; Piech CT
    Clin Ther; 2010 Feb; 32(2):238-45. PubMed ID: 20206781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
    Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.